CDTTW
MaterialsConduit Pharmaceuticals Inc Wt Exp
Live · NASDAQ · May 9, Close
What's Moving CDTTW Today?
No stock-specific AI insight has been generated for CDTTW yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.01
Fundamentals
Trading
CDTTW News
18 articles- CDT Notes Sarborg Filing of Substance of Matter Patent in Cystic Fibrosis MarketYahoo Finance·May 7, 2026
- CDT Advances AZD5904 into Global Patent Phase and Initiates Partnering DiscussionsYahoo Finance·May 6, 2026
- CDT Expands Multi-Pathway Value Creation Strategy Across Pharma, IP and AI-Driven DiscoveryYahoo Finance·Apr 16, 2026
- What's Going On With CDT Equity Shares On Monday?Benzinga·Apr 13, 2026
- CDT Notes Sarborg Publication of PRISM Framework Expanding AIYahoo Finance·Apr 7, 2026
- CDT Equity Expands Tapinarof Intellectual Property Portfolio with Two New Patent FilingsYahoo Finance·Mar 26, 2026
- CDT Equity Inc. Announces Reverse Stock SplitYahoo Finance·Mar 25, 2026
- CDT Identifies Rare Disease Opportunities Through Sarborg Signature Analysis, Advancing Out-Licensing StrategyYahoo Finance·Mar 23, 2026
- CDT Equity Stockholders Approve All Proposals at Special Meeting, Positioning the Company for Next Phase of GrowthYahoo Finance·Mar 18, 2026
- CDT Equity Notes Sarborg Expansion into Bacteria and AgrochemicalsYahoo Finance·Feb 24, 2026
- CDT Acquires Strategic Stake in Sarborg to Transform its AI-Driven Asset StrategyYahoo Finance·Feb 20, 2026
- CDT Equity Identifies New Biological Target Validating AI-Driven Repurposing StrategyYahoo Finance·Aug 26, 2025
- Conduit to Change Name to CDT Equity Inc.Yahoo Finance·Aug 5, 2025
- Conduit Pharmaceuticals Enters Joint Development Agreement with Manoira to Advance AZD1656 and AZD5658 in Animal HealthYahoo Finance·Jun 4, 2025
- Conduit Pharmaceuticals Inc. Listing on Nasdaq Capital MarketYahoo Finance·May 22, 2025
- Conduit Pharmaceuticals Inc. Regains Nasdaq ComplianceYahoo Finance·May 21, 2025
- Conduit Pharmaceuticals Inc. Announces Reverse Stock SplitYahoo Finance·May 16, 2025
- Conduit Pharmaceuticals Receives Further Patent Approval For Its Lead Asset Targeting Autoimmune DiseasesYahoo Finance·May 9, 2025
All 18 articles loaded
Price Data
52-Week Range
$0.01
Fundamentals
Trading
About Conduit Pharmaceuticals Inc Wt Exp
Conduit Pharmaceuticals Inc. is a forward-thinking biopharmaceutical company dedicated to developing innovative therapies for oncology and autoimmune disorders, addressing critical unmet medical needs. With its proprietary drug delivery platforms and a promising pipeline, the company aims to translate cutting-edge scientific research into effective clinical solutions that enhance patient outcomes. Conduit's strategic partnerships bolster its potential for treatment advancements, positioning it as a compelling investment opportunity in the rapidly evolving biotech landscape, especially as it continues to progress through key clinical trial phases.